免疫检查点抑制剂治疗小细胞肺癌的临床试验进展与应用
[Clinical Trial Progress and Application of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer].
作者信息
Zhang Huiqiu, Li Xiyang, Li Xichuan, Su Yanjun
机构信息
Tianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin 300387, China.
Key Laboratory of Cancer Prevention and Therapy, Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2021 Nov 20;24(11):790-795. doi: 10.3779/j.issn.1009-3419.2021.102.41.
Small cell lung cancer (SCLC) is a neuroendocrine tumor with fast progression, high malignancy, easy recurrence, and extremely poor prognosis. In the past 30 years, the clinical treatment strategy of SCLC has been mainly chemotherapy and radiotherapy, but the curative effect is not significant; the current immunotherapy of SCLC has gradually entered the clinic and has made certain progress. Tumor immunotherapy includes immune checkpoint inhibitors, tumor vaccines, cytokines, chimeric antigen receptor T-cell immunotherapy (CAR-T) therapy, etc. Currently, immune checkpoint inhibitors are the most widely used. This article summarizes the principles of immune checkpoint inhibitors and related drugs, summarizes their domestic and foreign clinical trials progress in SCLC treatment, reviews the biomarkers used in the therapy, and discusses its future development direction. .
小细胞肺癌（SCLC）是一种神经内分泌肿瘤，具有进展快、恶性程度高、易复发且预后极差的特点。在过去30年中，SCLC的临床治疗策略主要是化疗和放疗，但疗效并不显著；目前SCLC的免疫治疗已逐渐进入临床并取得了一定进展。肿瘤免疫治疗包括免疫检查点抑制剂、肿瘤疫苗、细胞因子、嵌合抗原受体T细胞免疫疗法（CAR-T）等。目前，免疫检查点抑制剂应用最为广泛。本文总结了免疫检查点抑制剂的原理及相关药物，概述了其在SCLC治疗中的国内外临床试验进展，回顾了治疗中使用的生物标志物，并探讨了其未来的发展方向。
Zotero 插件